Persistent Asset Partners’s SAB Biotherapeutics SABS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-25,400
Closed -$99.1K – 1021
2026
Q2
$99.1K Sell
25,400
-44,332
-64% -$165K 0.03% 295
2026
Q1
$267K Buy
69,732
+49,942
+252% +$199K 0.1% 163
2025
Q4
$74K Buy
+19,790
New +$65.1K 0.03% 280

Other funds holding SABS

Persistent Asset Partners's SABS Position: Q3 2026 in Review

Persistent Asset Partners sold out of SAB Biotherapeutics (SABS) in Q3 2026, closing a stake of 25,400 shares — an estimated $99.1K sold.

Persistent Asset Partners first reported a position in SABS in Q4 2025 and held it in 3 quarters. The position peaked at $267K in Q1 2026. 100 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

  • Persistent Asset Partners reported no remaining SAB Biotherapeutics position as of Q3 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 25,400 SAB Biotherapeutics shares in Q3 2026, an estimated $99.1K.
  • Persistent Asset Partners first reported a position in SAB Biotherapeutics in Q4 2025 and held it in 3 quarters.
  • Persistent Asset Partners's SAB Biotherapeutics position peaked at $267K in Q1 2026.
  • 100 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on Persistent Asset Partners's 13F filing for Q3 2026, filed 13 Nov 2026.